CombinatoRx Inc.'s shares jumped 33.3 percent Tuesday after the company and its U.S. commercialization partner Covidien plc said the FDA had approved Exalgo, a once-daily, extended-release formulation of hydromorphone, for moderate to severe pain in opioid-tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time. (BioWorld Today)